Advances in Neovascular Retinal Disease: A Case-Based, Data-Driven Guide to Treatment is organized by Healio.
Release Date: November 30, 2023
Expiration Date: November 30, 2024
Program Overview
Exciting new treatment advances offer viable alternatives to high-burden intravitreal vascular endothelial growth factor (VEGF) inhibitors for a wide range of patients with neovascular retinal diseases. Join our internationally renowned expert faculty as they discuss appropriate, evidence-based integration of novel agents into clinical practice using real-life case studies across several common disease states (neovascular age-related macular degeneration, diabetic macular edema, and macular edema secondary to retinal vein occlusion).
Learning Objectives
Upon completion of this activity, participants should be able to:
• Differentiate novel therapy from conventional intravitreal anti-VEGF therapy based on clinical trial data
• Evaluate data demonstrating differences in treatment and outcomes between patients with neovascular retinal diseases who are treated in the real world versus clinical trials
• Apply evolving clinical trial data and real-world data to determine treatment intervention for patients with neovascular retinal disease